Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma

Naoki Yajima, Ryuya Yamanaka, Takashi Mine, Naoto Tsuchiya, Jumpei Homma, Masakazu Sano, Terukazu Kuramoto, Yayoi Obata, Nobukazu Komatsu, Yoshimi Arima, Akira Yamada, Minoru Shigemori, Kyogo Itoh, Ryuichi Tanaka

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Purpose: The primary goal of this phase I study was to assess the safety and immunologic responses of personalized peptide vaccination for patients with advanced malignant glioma. Experimental Design: Twenty-five patients with advanced malignant glioma (8 grade 3 and 17 grade 4 gliomas) were evaluated in a phase I clinical study of a personalized peptide vaccination. For personalized peptide vaccination, prevaccination peripheral blood mononuclear cells and plasma were provided to examine cellular and humoral responses to 25 or 23 peptides in HLA-A24+ or HLA-A2+ patients, respectively; then, only the reactive peptides (maximum of four) were used for in vivo administration. Results: The protocols were well tolerated with local redness and swelling at the injection site in most cases. Twenty-one patients received more than six vaccinations and were evaluated for both immunologic and clinical responses. Increases in cellular or humoral responses specific to at least one of the vaccinated peptides were observed in the postvaccination (sixth) samples from 14 or 11 of 21 patients, respectively. More importantly, significant levels of peptide-specific IgG were detected in the postvaccination tumor cavity or spinal fluid of all of the tested patients who showed favorable clinical responses. Clinical responses were 5 partial responses, 8 cases of stable disease, and 8 cases of progressive disease. The median overall survival for patients with recurrent glioblastoma multiforme in this study (n = 17) was 622 days. Conclusions: Personalized peptide vaccinations were recommended for the further clinical study to malignant glioma patients.

Original languageEnglish
Pages (from-to)5900-5911
Number of pages12
JournalClinical Cancer Research
Volume11
Issue number16
DOIs
Publication statusPublished - 2005 Aug 15

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma'. Together they form a unique fingerprint.

  • Cite this

    Yajima, N., Yamanaka, R., Mine, T., Tsuchiya, N., Homma, J., Sano, M., Kuramoto, T., Obata, Y., Komatsu, N., Arima, Y., Yamada, A., Shigemori, M., Itoh, K., & Tanaka, R. (2005). Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clinical Cancer Research, 11(16), 5900-5911. https://doi.org/10.1158/1078-0432.CCR-05-0559